CHRS Earnings

Quarterly EPS
$-0.09
Q3 2024
$-0.44
Q4 2024
$-0.49
Q1 2025
$2.57
Q2 2025
$-0.31
Q3 2025
$-0.31
Q4 2025
$-0.28
Q1 2026
$-0.13
Q2 2026
Latest Revenue14.3M
Latest Net Income-20631000
EPS & Revenue Trend
PeriodEPSRevenueNet IncomeRev YoYEPS YoY
Q2 2026-$0.1314.3M-20631000+39.5%-105.1%
Q1 2026-$0.2812.3M-38327000+62.0%+42.9%
Q4 2025-$0.3112.7M-37643000+64.9%+29.5%
Q3 2025-$0.3111.6M-35531000+91.2%-244.4%
Q2 2025$2.5710.3M297.8M-0.4%+2,436.4%
Q1 2025-$0.497.6M-56569000+229.2%-153.8%
Q4 2024-$0.447.7M-50696000-91.6%+38.0%
Q3 2024-$0.096.1M-10751000-91.9%+78.0%
Q2 2024-$0.1110.3M-12921000
Q1 2024$0.912.3M102.9M
Q4 2023-$0.7191.5M-79653000
Q3 2023-$0.4174.6M-39641000
Coherus Oncology (CHRS) — Earnings